These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 14871992

  • 1. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
    Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM.
    Clin Cancer Res; 2004 Feb 01; 10(3):1121-9. PubMed ID: 14871992
    [Abstract] [Full Text] [Related]

  • 2. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S, Durrani FA, Rustum YM.
    Clin Colorectal Cancer; 2005 Jan 01; 4(5):336-43. PubMed ID: 15663838
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B, Cao S, Tóth K, Azrak RG, Rustum YM.
    Clin Cancer Res; 2000 Feb 01; 6(2):718-24. PubMed ID: 10690558
    [Abstract] [Full Text] [Related]

  • 4. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Apr 01; 10(7):2561-9. PubMed ID: 15073137
    [Abstract] [Full Text] [Related]

  • 5. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.
    Mol Cancer Ther; 2005 May 01; 4(5):843-54. PubMed ID: 15897249
    [Abstract] [Full Text] [Related]

  • 6. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
    Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Dec 01; 10(23):8005-17. PubMed ID: 15585636
    [Abstract] [Full Text] [Related]

  • 7. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM.
    Neoplasia; 2008 Aug 01; 10(8):857-65. PubMed ID: 18670644
    [Abstract] [Full Text] [Related]

  • 8. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S, Rustum YM.
    Cancer Res; 2000 Jul 15; 60(14):3717-21. PubMed ID: 10919639
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S, McGuire JJ, Rustum YM.
    Clin Cancer Res; 1999 Jul 15; 5(7):1925-34. PubMed ID: 10430100
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA, Cheshire PJ, Hallman JD, Lutz L, Luo X, Li Y, Houghton PJ.
    Clin Cancer Res; 1996 Jan 15; 2(1):107-18. PubMed ID: 9816097
    [Abstract] [Full Text] [Related]

  • 11. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT.
    J Control Release; 2015 Feb 10; 199():72-83. PubMed ID: 25497312
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K.
    Cancer Chemother Pharmacol; 1991 Feb 10; 28(3):192-8. PubMed ID: 1855276
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
    Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M.
    Oral Oncol; 2011 Jun 10; 47(6):459-66. PubMed ID: 21530364
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF, Prey J, Smith PF, Rustum YM.
    Biochem Pharmacol; 2007 May 01; 73(9):1280-7. PubMed ID: 17239826
    [Abstract] [Full Text] [Related]

  • 19. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
    Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD.
    J Clin Endocrinol Metab; 2006 Jan 01; 91(1):79-84. PubMed ID: 16263812
    [Abstract] [Full Text] [Related]

  • 20. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
    Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F.
    Cell Cycle; 2012 Nov 15; 11(22):4203-10. PubMed ID: 23095641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.